Periorbital fractional CO2 laser resurfacing has been employed for facial rejuvenation purposes. However, to the best of our knowledge, no study has objectively assessed periorbital neoformation and ...remodeling of local cutaneous collagen, in a split-face model, from skin samples obtained during upper blepharoplasty.
The authors sought to objectively evaluate neoformation and remodeling of local cutaneous collagen after periorbital skin fractional CO2 laser resurfacing.
Sixteen female patients presenting with dermatochalasis and periorbital rhytids were evaluated in a prospective and comparative study. All patients underwent unilateral periorbital fractional CO2 laser resurfacing 30 days before upper blepharoplasty. Quantification of types I and III collagen from laser-treated and untreated eyelid skin samples obtained during upper blepharoplasty was assessed with histochemical analysis (Picrosirius Red staining). Laser resurfacing treatment was applied to the untreated side immediately after the upper blepharoplasty. Two blinded, independent physicians evaluated clinical improvement in pretreatment and 1- and 6-month posttreatment digital images.
Histochemical analysis showed significantly higher intensity in collagen types I (treated: 158.7 ± 5.3, untreated: 139.2 ± 5.0; P < 0.0001) and III (treated: 105.1 ± 7.7, untreated: 104.1 ± 7.1; P < 0.0001) in the fractional CO2 laser treatment samples; a greater difference was detected in collagen type I. A significant improvement in periorbital rhytidosis was observed 1 month after laser resurfacing (23%); a greater improvement in the periorbital region was observed 6 months after laser resurfacing and upper blepharoplasty (43.67%).
Periorbital fractional CO2 laser resurfacing was an effective method to improve palpebral skin, with histochemical evidence of increase in collagen types I and III.
Spontaneous closure of a traumatic macular hole (TMH) is an unusual outcome. Optical coherence tomography (OCT) and clinical follow-up enabled monitoring of this resolution during a period of a few ...weeks. We describe a case of spontaneous closure of a TMH with complete visual recovery in a 15 year-old boy and show the follow-up of the macular hole obtained using the Spectral Domain OCT.
OBJETIVO: Avaliar as aberrações ópticas de alta ordem em pacientes com distonias faciais tratados com toxina botulínica tipo A. MÉTODOS: Pacientes com diagnóstico clínico de espasmo hemifacial ou ...blefaroespasmo essencial em atividade foram submetidos ao exame biomicroscópico e à análise de frente de ondas através do aberrômetro Alcon LADARvision®, sob midríase medicamentosa. A seguir, foram tratados com injeções de toxina botulínica tipo A. Após um mês, a análise de frente de ondas foi repetida da mesma forma e pelo mesmo oftalmologista. As aberrações de alta ordem foram comparadas antes e após o tratamento. O teste T pareado foi utilizado para comparar os valores numéricos antes e após o tratamento. RESULTADOS: Foram incluídos no estudo um total de 11 pacientes, 6 com blefaroespasmo essencial (54,5%) e 5 com espasmo hemifacial (45,5%). Nos pacientes com espasmo hemifacial foram analisados apenas o lado acometido, totalizando 17 olhos com espasmo. A idade variou de 50 a 72 anos, com média de 65,9 ± 8,2 anos. Oito pacientes eram do sexo feminino (72,7%), sendo a relação masculino/feminino de 1:2,6. A média do "root mean square" (RMS) das aberrações de alta ordem foi 0,68 antes e 0,63 após um mês do tratamento (p=0,01). A média da aberração esférica foi de 0,23 e 0,17 antes e após o tratamento respectivamente (p=0,01). Não houve diferenças estatisticamente significantes nos demais tipos de aberrações de alta ordem após o tratamento (p>0,05). CONCLUSÃO: O tratamento com toxina botulínica A pode diminuir as aberrações esféricas em pacientes com distonias faciais.
To analyze the ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin A.
Patients with benign essential blepharospasm and hemifacial spasm in activity underwent ...slit lamp examination and bilateral wavefront analysis under pharmacologic mydriasis using Alcon LADARvision wavefront aberrometry system. After that, all patients were treated with botulinum toxin A injections performed by the same ophthalmologist. After one month, the wavefront analysis was performed in the same way and by the same examiner. The main outcome measure was the change in ocular wavefront aberrations. Paired T-test was used to compare pre and post-injection numeric wavefront values.
From a total of 11 patients enrolled in this study, 6 (54.5%) had essential blepharospasm and 5 (45.5%) had hemifacial spasm. The fellow eyes of patients with hemifacial spasm were not included, totalizing 17 eyes with spasm. Eight patients were female (72.7%) and three were male (27.3%), the male:female ratio was 1:2.6. The age ranged from 50 to 72 years old with a mean of 65.9 ± 8.2 years. The mean of high order root mean square (RMS) wavefront aberrations was 0.68 before and 0.63 one month after the treatment (p=0.01). Before the treatment, the mean of spherical aberration was 0.23 and decreased to 0.17 one month after the treatment (p=0.01). There was no significant difference in the other higher-order aberrations before and after the treatment (p>0.05).
The treatment with botulium toxin may decrease spherical aberrations in patients with facial dystonia.
PDF
